Upstream Bio (UPB) Total Current Liabilities (2023 - 2026)

Upstream Bio's Total Current Liabilities history runs 4 years deep, the most recent figure standing at $13.7 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 42.88% year-over-year to $13.7 million; the TTM figure through Mar 2026 stood at $13.7 million (up 42.88% YoY), while the FY2025 annual figure was $13.5 million, up 25.29% from the prior year.
• Total Current Liabilities was $13.7 million for Q1 2026 at Upstream Bio, up from $13.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $13.7 million in Q1 2026 to a low of $6.5 million in Q4 2023.
• Historically, Total Current Liabilities has averaged $11.0 million across 4 years, with a median of $10.9 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities surged 64.8% in 2024, then gained 9.51% in 2025.
• A 4-year view of Total Current Liabilities shows it stood at $6.5 million in 2023, then soared by 64.8% to $10.7 million in 2024, then grew by 25.29% to $13.5 million in 2025, then advanced by 1.61% to $13.7 million in 2026.
• The last three Total Current Liabilities figures came in at $13.7 million (Q1 2026), $13.5 million (Q4 2025), and $11.9 million (Q3 2025), per Business Quant data.